Welcome!

News Feed Item

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Jan. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0843003/Urinary-Tract-Infections-UTI-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy  

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Urinary Tract Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Urinary Tract Infections Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Urinary Tract Infections Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Urinary Tract Infections Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Urinary Tract Infections Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Urinary Tract Infections Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Urinary Tract Infections Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Urinary Tract Infections Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Urinary Tract Infections Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 UTI Therapeutics - Introduction 72.1 Overview 72.2 Classification of UTI 72.2.1 Site of Infection 82.2.2 Based On Symptoms 82.2.3 Based on Recurrence 82.2.4 Based on Complicating Factors 82.2.5 Based on Origin of Infection 82.3 Epidemiology 92.4 Etiology 102.5 Risk Factors 102.6 Signs and Symptoms 112.7 Pathophysiology of UTI 112.8 Diagnosis and Treatment of UTI 122.9 GlobalData Pipeline Report Guidance 163 UTI Therapeutics - Market Characterization 173.1 UTI Therapeutics Market Size (2005-2010) - Global 173.2 UTI Therapeutics Market Forecast (2010-2018) - Global 193.3 UTI Therapeutics Market Size (2005-2010) - The US 213.4 UTI Therapeutics Market Forecast (2010-2018) - The US 223.5 UTI Therapeutics Market Size (2005-2010) - France 233.6 UTI Therapeutics Market Forecast (2010-2018) - France 243.7 UTI Therapeutics Market Size (2005-2010) - Germany 253.8 UTI Therapeutics Market Forecast (2010-2018) - Germany 263.9 UTI Therapeutics Market Size (2005-2010) - Italy 273.10 UTI Therapeutics Market Forecast (2010-2018) - Italy 283.11 UTI Therapeutics Market Size (2005-2010) - Spain 293.12 UTI Therapeutics Market Forecast (2010-2018) - Spain 303.13 UTI Therapeutics Market Size (2005-2010) - The UK 313.14 UTI Therapeutics Market Forecast (2010-2018) - The UK 323.15 UTI Therapeutics Market Size (2005-2010) - Japan 333.16 UTI Therapeutics Market Forecast (2010-2018) - Japan 343.17 Drivers and Barriers for the UTI Therapeutics Market 353.17.1 Drivers for the UTI Therapeutics Market 353.17.2 Barriers for the UTI Therapeutics Market 353.18 Key Events Impacting the Future Market 363.19 Opportunity and Unmet Need 363.20 Key Takeaway 374 UTI Therapeutics Market - Competitive Assessment 384.1 Overview 384.1.1 Strategic Competitor Assessment 384.2 Profiles of Commonly Used Products in the UTI Therapeutics Market 394.2.1 Ciprofloxacin 394.2.2 Doribax (doripenem) 404.2.3 Invanz (ertapenem sodium) 414.2.4 Levaquin (levofloxacin) 424.2.5 Fosfomycin tromethamine 424.2.6 Macrobid/Macrodantin (nitrofurantoin) 434.2.7 Bactrim/Septra (trimethoprim/sulfamethoxazole) 444.3 Key Takeaway 445 UTI Therapeutics Market - Pipeline Assessment 455.1 Overview 455.2 Strategic Pipeline Assessment 455.2.1 UTI Therapeutics - Phase III Pipeline 465.2.2 UTI Therapeutics - Phase II Pipeline 465.2.3 UTI Therapeutics – Phase I Pipeline 465.3 UTI Pipeline by Mechanism of Action 475.4 UTI Technology Trends Analytical Framework 485.5 UTI Therapeutics - Late-stage Drugs under Clinical Development 495.6 Molecule Profile for Late-stage Drugs under Clinical Development 505.6.1 CXA-201 (CXA-101/tazobactam) 505.6.2 CAZ-AVI (Avibactam/ceftazidime) 505.7 Key Takeaway 516 UTI Therapeutics - Clinical Trials Mapping 526.1 Clinical Trials by Country (US, EU5 and Japan) 526.2 Clinical Trials by Phase 536.3 Clinical Trials by Trial Status 546.4 Overall Sponsors 556.5 Prominent Sponsors 566.6 Top Companies Participating in UTI Therapeutics Clinical Trials 577 UTI Therapeutics - Strategic Assessment 587.1 UTI Therapeutics - Implications for Future Market Competition 588 UTI Therapeutics - Future Players 598.1 Introduction 598.1.1 AstraZeneca PLC 598.1.2 Cubist Pharmaceuticals 618.1.3 Forest Laboratories 639 UTI Therapeutics - Licensing and Partnership Deals 6510 UTI Therapeutics - Appendix 6710.1 Definitions 6710.2 Acronyms 6710.3 Research Methodology 6810.3.1 Coverage 6810.3.2 Secondary Research 6810.3.3 Forecasting 6910.3.4 Primary Research 7110.3.5 Expert Panel Validation 7110.4 Contact Us 7110.5 Disclaimer 7110.6 Bibliography 72

List of Tables

Table 1: UTI - Prevalence, Major Markets, 2010 9Table 2: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17Table 3: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19Table 4: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21Table 5: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22Table 6: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23Table 7: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24Table 8: UTI Therapeutics Market, Germany, Revenue ($m), 2005-2010 25Table 9: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26Table 10: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27Table 11: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28Table 12: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29Table 13: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30Table 14: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31Table 15: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32Table 16: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33Table 17: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34Table 18: UTI Therapeutics - Phase III Pipeline 46Table 19: UTI Therapeutics - Phase II Pipeline 46Table 20: UTI Therapeutics – Phase I Pipeline 46Table 21: UTI Therapeutics - Late-stage Drugs Under Clinical Development, 2011 49Table 22: UTI Therapeutics - Clinical Trials by Country, 2011 52Table 23: UTI Therapeutics - Clinical Trials by Phase, 2011 53Table 24: UTI Therapeutics - Clinical Trials by Status, 2011 54Table 25: UTI Therapeutics, Overall Sponsors, 2011 55Table 26: UTI Therapeutics - Prominent Sponsors, 2011 56Table 27: UTI Therapeutics - Top Companies Participating in Clinical Trials, 2011 57Table 28: AstraZeneca Infectious Disease Pipeline, 2011 61Table 29: Cubist Pharmaceuticals Infectious Disease Pipeline, 2011 62Table 30: Forest Laboratories - Infectious Disease Pipeline, 2011 64Table 31: Licensing and Partnership Deals 65

List of Figures

Figure 1: Classification of UTI 7Figure 2: Principal Pathogens of UTI 10Figure 3: Symptoms of UTI 11Figure 4: Diagnostic Approach to UTI in Adults 12Figure 5: Different Class of Antibiotics Used for UTI 13Figure 6: Diagnosis and Treatment of UTI 14Figure 7: Diagnosis and Treatment of UTI 15Figure 8: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17Figure 9: UTI Therapeutics, Market Share ($m, %), 2010 18Figure 10: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19Figure 11: UTI Therapeutics, Market Share ($m, %), 2018 20Figure 12: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21Figure 13: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22Figure 14: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23Figure 15: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24Figure 16: UTI Therapeutics Market, Germany , Revenue ($m), 2005-2010 25Figure 17: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26Figure 18: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27Figure 19: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28Figure 20: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29Figure 21: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30Figure 22: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31Figure 23: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32Figure 24: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33Figure 25: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34Figure 26: UTI Therapeutics Market , Key Events Impacting the Future Market 36Figure 27: Opportunity and Unmet Need in the UTI Therapeutics Market, 2011 37Figure 28: UTI Therapeutics - Strategic Competitor Assessment, 2011 39Figure 29: UTI Therapeutics - Pipeline by Phase of Clinical Development, 2011 45Figure 30: UTI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 47Figure 31: Technology Trends Analytical Framework of the UTI Pipeline, 2011 48Figure 32: Technology Trends Analytical Framework of The UTI Therapeutics Pipeline - Description, 2011 49Figure 33: UTI Therapeutics - Clinical Trials by Country, 2011 52Figure 34: UTI Therapeutics - Clinical Trials by Phase, 2011 53Figure 35: UTI Therapeutics - Clinical Trials by Status, 2011 54Figure 36: UTI Therapeutics - Overall Sponsors, 2011 55Figure 37: UTI Therapeutics - Prominent Sponsors, 2011 56Figure 38: UTI Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 57Figure 39: Implications for Future Market Competition in the UTI Therapeutics Market, 2011 58Figure 40: UTI Therapeutics Market - Clinical Pipeline by Company, 2011 59Figure 41: GlobalData Market Forecasting Model 70

Companies mentioned

AstraZeneca PLC

Cubist Pharmaceuticals

Forest Laboratories

To order this report: Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
StarNet Communications Corp has announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 to safely tunnel the remote desktops from Linux and Unix servers to the user’s PC over encrypted SSH. Traditionally, users of PC X servers deploy the XDMCP protocol to display remote desktop environments such as the Gnome and KDE desktops on Linux servers and the CDE environment on Solaris Unix machines. XDMCP is used primarily on comp...
Enterprises have forever faced challenges surrounding the sharing of their intellectual property. Emerging cloud adoption has made it more compelling for enterprises to digitize their content, making them available over a wide variety of devices across the Internet. In his session at 19th Cloud Expo, Santosh Ahuja, Director of Architecture at Impiger Technologies, will introduce various mechanisms provided by cloud service providers today to manage and share digital content in a secure manner....
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...